1.Kumar S, Nandi A, Singh S, Regulapati R, Li N, Tobias J, Siebel C, Blanco M, Klein-Szanto A, Lengner C, Welm A, Kang Y, Chakrabarti R. Author Correction: Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway. Nat Commun. 2022;13(1):3927. PMCID: PMC9262875 Reference Link
1.Kumar S, Nandi A, Singh S, Regulapati R, Li N, Tobias J, Siebel C, Blanco M, Klein-Szanto A, Lengner C, Welm A, Kang Y, Chakrabarti R. Dll1 quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway. Nat Commun. 2021;12(1):432. PMCID: PMC7813834 Reference Link
1.Song K, Cai X, Dong Y, Wu H, Wei Y, Shankavaram U, Cui K, Lee Y, Zhu B, Bhattacharjee S, Wang B, Zhang K, Wen A, Wong S, Yu L, Xia L, Welm A, Bielenberg D, Camphausen K, Kang Y, Chen H. Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development. J Clin Invest. 2021;131(1). PMCID: PMC7773373 Reference Link
1.Zijlstra A, Von Lersner A, Yu D, Borrello L, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox T, Price J, Kato Y, Welm A, Aguirre-Ghiso J, Board Members of the Metastasis Research Society. The importance of developing therapies targeting the biological spectrum of metastatic disease. Clin Exp Metastasis. 2019;36(4):305–309. PMCID: PMC8794535 Reference Link
